PALM BEACH, Florida, April 6, 2017 /PRNewswire/ --
MarketNewsUpdates.com News Commentary
Asthe business of cannabis continues to develop into a lucrative industry, entrepreneurs, investors and industry advocates are recognizing key opportunities to capitalize on the momentum and steadily rising revenues. A few notable companies in the industry
International Canna Pro Expo Connects Healthcare Professionals, Investors, and Entrepreneurs Interested in the Business of Medical Cannabis - When considering North American sales of medical and recreational cannabis grew by an unprecedented 30% in 2016, the accelerating pace of legalization across the United States, and an ever-expanding list of medicinal uses, it's no surprise why savvy investors are flocking to medical cannabis to claim their stake in the industry.
At the fore front of this financial tidal wave comes the International Canna Pro Expo (ICPE), a medical cannabis industry conference for healthcare and business professionals, June 24 - 25, 2017, at the Sheraton Hotel Downtown in Philadelphia, PA. Read more about ICPE operations at: http://marketnewsupdates.com/news/cpexpo.html
The ICPE will connect entrepreneurs, investors, medical professionals, and advocates through a variety of engaging panel discussions, industry trend topics, scientific lectures, and networking opportunities, designed to build relationships within the medical cannabis business community while providing credible, academic, and fact-based insight from leaders in the industry.
"I'm constantly meeting doctors and health care professionals who are eager for reputable, evidence-based information on medical cannabis. This Expo is their chance to find it," said the ICPE's keynote speaker and longtime medical cannabis supporter, Montel Williams.
Since being diagnosed with multiple sclerosis in 1999-the symptoms of which he manages with medical cannabis products-the Emmy award-winning talk show host has been an outspoken advocate in the fight for medical cannabis law reform.
Alongside Montel Williams, the ICPE will feature an array of cannabis-connected business and healthcare leaders, including an investors panel headed by Lindy Snider, CEO of Lindi Skin, active investor, and business advisor in the cannabis venture space; and presentations by Dr. Charles Pollack, Associate Provost for Innovation in Education at Thomas Jefferson University and Director of the Lambert Center for the Study of Medicinal Cannabis and Hemp and, Michael C. Minardi, Senior Partner at Minardi Law, a legal firm specializing in corporate consulting services for clients entering the cannabis industry.
After last year's historic election, nearly 190 million, or 60% of Americans, now live in states where medical cannabis has been legalized to some degree. This not only presents a huge opportunity for traditional venture capitalists but also for doctors and other healthcare professionals, who are quickly becoming a significant investment group in the medical cannabis market.
"I have also found that doctors are one of the largest sectors of investors and participants in the medical cannabis industry. Many are on advisories and boards, as well," said Lindy Snider, who has seen numerous physicians adopt medical cannabis as a means to expand their practice and become part of a budding industry.
Backed with more than 25 years of medical conference and investor experience, the International Canna Pro Expo is where the healthcare community, medical cannabis industry influencers, investors and business owners gather, to network and learn about the opportunities associated with the progression of medical cannabis as a medicine. The event is open to all who wish to register and attend. Learn more by visiting the ICPE's website: InternationalCannaProExpo.com
In recent and current developments of key industry related companies of note:
InMed Pharmaceuticals Inc. (OTCQB: IMLFF) (CSE: IN.CN) was a strong performer in the markets yesterday, closing up over 35% on the U.S. OTC market at $0.5692, trading over 4.2 Million shares as well as closing up over 33% on the CSE Canadian Exchange at $0.76, trading over 4.1 Million shares by the market close. InMed Pharmaceuticals Inc., a pre-clinical stage biopharmaceutical company, engages in the research and development of novel and cannabinoid-based therapies in Canada.
GW Pharmaceuticals plc (NASDAQ: GWPH), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, at the end of this past March announced that the European Medicines Agency (EMA) has granted Orphan Drug Designation to GW's investigational product Epidiolex® (cannabidiol or CBD) used in the treatment of Lennox-Gastaut Syndrome (LGS), a treatment-resistant, debilitating childhood-onset epilepsy.
Por Grace Foundation, a Mexican national reference of the fight to gain access to cannabis derived products for the treatment of several neurodegenerative conditions, yesterday announced the results of a new survey from the viewpoint of the parents of children with refractory epilepsy (RE). Conducted by renowned Mexico Physician Dr. Carlos G. Aguirre Velazquez, the study found that out of 43 cases of children who were treated with cannabidiol (CBD) hemp oil, over 81% showed a reduction in convulsions. Additionally, these new study results have been published in Neurology Research International. The product most commonly used in the survey was Medical Marijuana, Inc.'s (OTC: MJNA) subsidiary HempMeds® Mexico's flagship product, Real Scientific Hemp Oil-X™ (RSHO-X™). RSHO-X™ was the first product to receive COFEPRIS approval for import into Mexico and is 100% THC-free.
OWC Pharmaceutical Research Corp. (OTCQB: OWCP), an Israeli-based research company engaged in the development of cannabinoid-based therapies targeting a variety of different medical conditions and disorders, yesterday announced it has received expressions of interest from the scientific and medical communities world-wide, as a result of its recently announce positive preliminary clinical efficacy tests results of its topical cream to treat Psoriasis.
Terra Tech Corp. (OTCQX: TRTC), a vertically integrated cannabis-focused agriculture company, at the end of March announced its financial results for the year ending December 31, 2016. Highlights included: Total revenues for the full year 2016 were $25.33 million, an increase of 154% from $9.98 million in the year ended December 31, 2015; Total revenues generated for the quarter ended December 31, 2016 were approximately $7.13 million, an increase of 229% from $2.17 million in the same period in 2015. - Gross margin for the year ended December 31, 2016 amounted to approximately 10.2%, compared to approximately 10.2% for the year ended December 31, 2015. - Selling, general and administrative expenses for the year ended December 31, 2016 amounted to approximately $20.72 million, compared to approximately $9.83 million for the year ended December 31, 2015. - The net loss attributable to Terra Tech for the year ended December 31, 2016 was approximately $26.92 million or ($0.07) per share, compared to a loss of approximately $9.23 million or ($0.04) per share for the year ended December 31, 2015. The increase in net loss is primarily attributable to an increase in sales, general and administrative expenses, an increase in other income (expense), and an increase in the loss associated with the issuance of convertible debt and warrants during the year ended December 31, 2016, compared to the prior year. Read the entire report at: http://finance.yahoo.com/news/terra-tech-corp-reports-record-202500429.html
DISCLAIMER: MarketNewsUpdates.com (MNU) is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. MNU is NOT affiliated in any manner with any company mentioned herein. MNU and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. MNU's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. MNU is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed MNU was not compensated by any public company listed herein. MNU HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and MNU undertakes no obligation to update such statements.
Contact Information: Media Contact E-mail: firstname.lastname@example.org Phone: +1-561-325-8757
Subscribe to our Free Newsletters!
Steroids are miracle drugs but have to be used with caution. Some steroids are illegal to use, ...
Abruptio placenta is a serious but rare complication of pregnancy where a separation of placenta ...
Cyanosis is the bluish or purplish discoloration of the skin and mucus membranes due to lack of ...View All